文献速递心脑血管急症重症综合管理与镇静镇痛

重型抗N-甲基-D-天冬氨酸受体脑炎患者的临床特征与预后

Clinical Characteristics and Prognosis of Severe Anti-N-methyl-D-aspartate Receptor Encephalitis Patients.
PubMed 文献 · Neurocrit Care · 2018-01-01
一句话结论重型抗NMDAR脑炎患者经早期、积极、不间断的联合免疫治疗与生命支持后,多数最终获得良好长期预后,6个月及长期随访预后与非重型组无显著差异。

该观察性研究纳入111例抗NMDAR脑炎患者(男59例、女52例,平均年龄27.7±13.7岁),按入住神经重症监护病房时的特征分为重型组39例(35.1%)与非重型组72例(64.9%)。重型组癫痫发作、不自主运动、意识障碍、自主神经功能障碍和中枢性低通气的比例更高;重型组脑脊液NMDAR抗体强阳性比例48.7%高于非重型组29.2%;全部患者脑脊液NMDAR抗体均阳性,仅57例(51.4%)血清NMDAR抗体阳性。重型组接受静脉注射免疫球蛋白的比例高于非重型组(P=0.003),仅重型组接受血浆置换、静脉利妥昔单抗和环磷酰胺治疗。6个月及长期随访时两组预后无显著差异。

要点

  • 111例抗NMDAR脑炎中重型组39例(35.1%),非重型组72例(64.9%),平均年龄27.7±13.7岁。
  • 重型组较非重型组更常见癫痫发作、不自主运动、意识障碍、自主神经功能障碍和中枢性低通气。
  • 全部患者脑脊液NMDAR抗体阳性,仅57例(51.4%)血清NMDAR抗体阳性;重型组抗体强阳性48.7%高于非重型组29.2%。
  • 重型组接受静脉注射免疫球蛋白比例高于非重型组(P=0.003),仅重型组接受血浆置换、静脉利妥昔单抗和环磷酰胺。
  • 6个月及长期随访时重型组与非重型组预后无显著差异,多数重型患者经早期积极不间断联合免疫治疗与生命支持后最终预后良好。

适用人群与场景

  • 入住神经重症监护病房的抗NMDAR脑炎患者,按入院时特征分为重型组与非重型组。
  • 研究纳入111例患者,男59例、女52例,平均年龄27.7±13.7岁。

处置流程与药物剂量

  • 重型组接受静脉注射免疫球蛋白的比例高于非重型组(P=0.003)。
  • 仅重型组接受血浆置换、静脉利妥昔单抗和环磷酰胺治疗。
  • 作者结论认为,重型患者经早期、积极、不间断的联合免疫治疗与生命支持后多数最终获得良好长期预后。

红旗征与不能漏的情况

  • 重型组较非重型组更常见癫痫发作、不自主运动、意识障碍、自主神经功能障碍和中枢性低通气。

研究设计与关键结果

  • 观察性研究纳入111例抗NMDAR脑炎患者,重型组39例(35.1%),非重型组72例(64.9%)。
  • 重型组癫痫发作、不自主运动、意识障碍、自主神经功能障碍和中枢性低通气比例高于非重型组。
  • 全部患者脑脊液NMDAR抗体阳性,仅57例(51.4%)血清NMDAR抗体阳性;重型组抗体强阳性48.7%高于非重型组29.2%。
  • 重型组接受静脉注射免疫球蛋白比例高于非重型组(P=0.003),仅重型组接受血浆置换、静脉利妥昔单抗和环磷酰胺。
  • 6个月及长期随访时重型组与非重型组预后无显著差异。

证据类型、等级与局限

  • 证据类型:观察性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对入住神经重症监护病房的抗NMDAR脑炎患者,应识别癫痫发作、不自主运动、意识障碍、自主神经功能障碍和中枢性低通气等重型表现。
  • 脑脊液NMDAR抗体检测对抗NMDAR脑炎诊断价值高于血清检测(全部患者脑脊液阳性,仅51.4%血清阳性)。
  • 作者认为,重型患者经早期、积极、不间断的联合免疫治疗与生命支持后多数最终获得良好长期预后。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: Data concerning the characteristics and duration of the critical manifestations, treatment response, and long-term outcomes of severe anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis patients compared to those of non-severe patients are limited. This observational study was performed to explore the clinical characteristics and long-term outcomes of severe anti-NMDAR encephalitis patients.

METHODS: According to their characteristics on admission to the neurology intensive care unit, patients with anti-NMDAR encephalitis were divided into a severe group and a non-severe group. The demographics, clinical manifestations, main accessory examinations, immunotherapy, and outcomes of patients were recorded. Statistical analyses were employed to examine the differences in each observed indicator between the severe and non-severe groups.

RESULTS: This study enrolled 111 patients with anti-NMDAR encephalitis, including 59 males and 52 females with a mean age of 27.7 ± 13.7 years; 39 (35.1%) patients were in the severe group, and 72 (64.9%) patients were in the non-severe group. Compared to the non-severe group, the severe group exhibited a higher proportion of epilepsy, involuntary movement, disturbance of consciousness, autonomic dysfunction, and central hypoventilation. The cerebrospinal fluid (CSF) of all patients was positive for the NMDAR antibody, but only 57 patients (51.4%) tested positive for the NMDAR antibody in the blood. The proportion of patients with a strong positive NMDAR antibody titer in the severe group (48.7%) was higher than that in the non-severe group (29.2%). The proportion of patients receiving intravenous gamma immunoglobulin in the severe group was higher than that in the non-severe group (P = 0.003), and only patients in the severe group received plasma exchange, intravenous rituximab, and cyclophosphamide treatment. No significant difference was observed in the prognosis between the severe group and the non-severe group after 6 months and during long-term follow-up.

CONCLUSION: Most severe anti-NMDAR encephalitis patients will eventually achieve good long-term prognoses after receiving early, positive and unremitting combined immunotherapy and life support.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Zhang Y, Liu G, Jiang M, et al. Clinical Characteristics and Prognosis of Severe Anti-N-methyl-D-aspartate Receptor Encephalitis Patients. Neurocrit Care. 2018. PMID: 29651625. doi:10.1007/s12028-018-0536-6

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。